AusBiotech offers clarification on tax incentives to keep research within Australia

7 April 2016
2019_biotech_test_vial_discovery_big

The trade group representing Australia’s biotech industry has moved to clear up confusion over the proposed Australian Innovation and Manufacturing’ (AIM) Incentive.

AusBiotech and others have called for the introduction of this incentive in order to make sure Australian research and development-based intellectual property (IP) is developed and supported within Australia, delivering value to the country and its biotech industry as it reaches commercialization.

The group has now responded to criticism of AIM by accusing critics of not reading the proposal correctly.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology